Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and Shenzhen Yuanxing Gene-tech Co.,Ltd., have agreed to cooperate in the manufacture of over 60 million doses of the Sputnik V vaccine, RDIF informed.
To date, Sputnik V has been registered in 57 countries globally with total population of over 1.5 billion people. The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two vaccination shots.
